Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)

Organon

Status and phase: Completed; Phase 3

Conditions: Hypercholesterolemia

Treatments: Drug: Comparator: atorvastatin / Duration of Treatment: 28 weeks; Drug: MK0653, ezetimibe / Duration of Treatment: 28 weeks

Study type: Interventional

Funder types: Industry

Identifiers

NCT00092716

2004_047

0653-025

Details and patient eligibility

About

The purpose of this study is to determine whether an investigational medication will be more effective than an approved medication in reducing cholesterol levels.

Enrollment: 655 patients

Sex: All

Ages: 18 to 79 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Elevated cholesterol levels

Exclusion criteria

• Liver disease
• Unstable medical conditions

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind